Wockhardt Limited · NSE:WOCKPHARMA
Wockhardt — Investor Presentation (February 2013)
33 slides from Wockhardt's investor presentation, February 2013
Slide 1: Wockhardt Limited Investor Presentation
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director February 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement • Except for historical information contained herein, statements in this communication, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “
Slide 3: Introduction to Wockhardt
Introduction to Wockhardt Key business Dynamics
Slide 4: Wockhardt Today
Wockhardt Today UK, Ireland, France, Switz. USA Direct Operations in India, USA Mexico India and Europe 7900 Associates employed in 21 countries Wockhardt Direct ROW operations operations Investor Presentation Feb 2013 4
Slide 5: Wockhardt Today
Wockhardt Today UK Ireland 9 sites Chicago in India 12 Baddi Manufacturing Locations globally Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Formulations APIs Investor Presentation Feb 2013 5
Slide 6: Wockhardt Today R&D Centers
Wockhardt Today 3 R&D Centers worldwide USA / UK & India Investor Presentation Feb 2013 6
Slide 7: Sustainable Business Model
Sustainable Business Model Research WOCKHARDT Operational Globalisation Excellence Investor Presentation Feb 2013 7
Slide 8: Research
Research New Chemical Generics Biosimilars Entity Complex Anti Insulins Technology Infectives Niche MABs Blockbuster Investor Presentation Feb 2013 8
Slide 9: Sustainable Business Model
Sustainable Business Model Research WOCKHARDT Operational Globalisation Excellence Investor Presentation Feb 2013 9
Slide 10: Global Operations
Global Operations Wockhardt Direct operations RoW operations UK, Ireland, France, Switz. USA Mexico India Investor Presentation Feb 2013 10
Slide 11: Geographical Split
Geographical Split Increased presence in High Growth, High Profit geography. Above numbers based on Revenues excluding Nutrition Business revenues Investor Presentation Feb 2013 11
Slide 12: Sustainable Business Model
Sustainable Business Model Research WOCKHARDT Operational Globalisation Excellence Investor Presentation Feb 2013 12
Slide 13: Fit & Trim Operations
Fit & Trim Operations Gross Margins at 68% in 9MFY13 64% in FY12 EBITDA Margins at 38% in 9MFY13 31% in FY12 18% in FY10. Operating Expenses at 32% in 9MFY13 32% in FY12 40% in FY08. Investor Presentation Feb 2013 13
Slide 14: Q3 Results
Q3 Results TWOCKHARDT
Slide 15: Q3 Results - Note
Q3 Results - Note • The results discussed in the following slides have been normalized for the following for all the previous comparative periods 1. Nutrition Business Revenues and Profits and 2. Research & Development Costs Investor Presentation Feb 2013 15
Slide 16: Sales – Growth of 26% over Q3FY12
Sales – Growth of 26% over Q3FY12 Growth of 26% over Q3FY12 Growth of 30% in 9MFY13 over 9MFY12 Investor Presentation Feb 2013 16
Slide 17: EBITDA – Growth of 63% over Q3FY12
EBITDA – Growth of 63% over Q3FY12 Growth of 63% over Q3FY12 Growth of 71% in 9MFY13 over 9MFY12 12th Consecutive Quarter of Sequential Growth Investor Presentation Feb 2013 17
Slide 18: Adj. PAT – Growth of 139% over Q3FY12
Adj. PAT – Growth of 139% over Q3FY12 Growth of 139% over Q3FY12 Growth of 185% in 9MFY13 over 9MFY12 Investor Presentation Feb 2013 18
Slide 19: Quarter on Quarter Improvement
Quarter on Quarter Improvement Investor Presentation Feb 2013 19
Slide 20: Financial Highlights
Financial Highlights • Free Cash Flow from operations in excess of Rs.275 crores in Q3FY13 and above Rs. 800 crores for 9MFY13. • Exit from CDR on target. • Total Debt repaid during the year in excess of Rs.1600 crores till date. • Net interest cost stand at around 4.2% on an annualized basis (at ar
Slide 21: US Business: Profitable Growth
US Business: Profitable Growth • Growth of 45% (26% on $terms) over Q3FY12. • Growth in 9MFY13 of 55% (30% in $ terms) over 9MFY12 • 3 New Products launched in Q3FY13. A total of 11 new product launches in 9MFY13. • Growth driven by niche launches made during 2012 like generic version of brands like
Slide 22: EU Operations: Strong UK Operations
EU Operations: Strong UK Operations UK Operations • UK operation grows by 19% (4% in £ terms) in Q3FY13 against a stagnant market growth • Growth of 25% (7% in £ terms) in 9MFY13 • 2 new product launches in Q3FY13, 8 in 9MFY13 • No. 3 Generic company in UK • No. 2 in the hospital segment Ireland Ope
Slide 23: Emerging Markets
Emerging Markets • Emerging Markets growth at 15% for Q3FY13 and at 15% for 9MFY13. • Indian Business grew at 14% over Q3FY12. • Restructuring of the India field force has started showing some positive results. • ROW operations grew by 18% over Q3FY12 Investor Presentation Feb 2013 23
Slide 24: Awards
Awards BEST ENTERPRISE WOCKHARDT By Europe Business Assembly PHARMEXCIL AWARD WOCKHARDT for highest no. of Patents filed for the 4th year in a row DIANA AWARD WOCKHARDT USA Inc. Healthcare Distribution Management Association (HDMA) USA FROST & SULLIVAN CHAIRMAN India Healthcare Excellence Awards Lif
Slide 25: Peer Positioning
Peer Positioning TWOCKHARDT
Slide 26: Peer Positioning – 9M & Q3FY13 Sales Growth
Peer Positioning – 9M & Q3FY13 Top 3 8213 Sales Growth 7055 2501 1382 2865 4124 1435 3678 6221 4746 8213 1604 2070 2865 Rs. crores Investor Presentation Feb 2013 26
Slide 27: Peer Positioning – 9M & Q3FY13 EBITDA Growth
Peer Positioning – 9M & Q3FY13 Top 3 320 EBITDA Growth 1545 3692 605 545 1595 1710 1275 493 757 843 1758 255 567 Rs. crores Investor Presentation Feb 2013 27
Slide 28: Peer Positioning – 9M & Q3FY13 EBITDA Margin
Peer Positioning – 9M & Q3FY13 Top 3 EBITDA Margin Investor Presentation Feb 2013 28
Slide 29: Peer Positioning – 9M & Q3FY13 PAT & PAT Growth
Peer Positioning – 9M & Q3FY13 Top 3 1259 213 PAT & PAT Growth 428 1240 448 335 881 339 906 1997 1107 363 393 103 Rs. crores Investor Presentation Feb 2013 29
Slide 30: Peer Positioning – 9M & Q3FY13 PAT Margins
Peer Positioning – 9M & Q3FY13 Top 3 PAT Margins Investor Presentation Feb 2013 30
Slide 31: Consistent Profitable Growth
Consistent Profitable Growth
Slide 32: Delivering Consistent Profits
Delivering Consistent Profits • R&D at the Strategic Core Research • Robust Product Pipeline • Direct Operations in USA, UK , Ireland & India Globalization • Strategic Alliances in Emerging Economies • Strong Management & Research Capabilities Operational • Focus on High Value Product Launches Excel
Slide 33: For investor updates and communication please visit www.wockhardt.com
For investor updates and communication please visit www.wockhardt.com For Information please contact Tushar Mistry Tel.: +91 22 26596210 tmistry@wockhardt.com 33 Investor Presentation Feb 2013